PharmaceuticalTechnology.com
Unlike the rest of the world, New Zealand’s speedy and decisive response to Covid-19 has successfully enabled the country’s clinical trials to continue largely unscathed. Allie Nawrat talks to key actors in the New Zealand clinical space about how Covid-19 has positively impacted the country’s trial landscape, as well as how to ensure this success is long-term.